A5053583146- Gut microbiota and health
- Inflammatory Bowel Disease
- Clostridium difficile and Clostridium perfringens research
- Probiotics and Fermented Foods
- Drug Transport and Resistance Mechanisms
- Cancer Immunotherapy and Biomarkers
- Gastrointestinal motility and disorders
- Stress Responses and Cortisol
Centre Hospitalier de l’Université de Montréal
2024-2025
Shanghai Jiao Tong University
2022-2024
The pathogenesis of ulcerative colitis (UC) is complicated with impaired intestinal epithelial barrier and imbalanced gut microbiota. Both selenium probiotics have shown effects in regulating flora ameliorating UC. objective this study to investigate the alleviating Selenium-enriched Bifidobacterium longum DD98 (Se-B. DD98) on dextran sulfate sodium (DSS)-induced mice explore underlying mechanism. After treatment B. DD98, Se-B. sulfasalazine for 3 weeks, disease severity UC was decreased,...
Irritable bowel syndrome (IBS) is a functional intestinal disorder without clear pathological mechanisms. Classical treatments for IBS are not always effective and usually accompanied by side effects. Selenium-enriched Bifidobacterium longum DD98 (Se-B. DD98) selenized probiotic strain which has shown many beneficial effects on the gastrointestinal tract, but its underlying mechanism unclear. This study aims to investigate relieving of Se-B. chronic unpredictable mild stress (CUMS)-induced...
Abstract Introduction: Several strategies to improve immune checkpoint inhibitors (ICI) activity are under evaluation. Pre-clinical murine studies have shown the potential of castalagin, a prebiotic polyphenol extracted from Camu (CC) berry beneficially shift microbiome and metabolites leading enhanced ICI response. We tested CC, an approved natural product, in trial combined with melanoma (MM) non-small cell lung cancer (NSCLC). Methods: completed phase I combining 1.5g daily CC oral...
Background: Trials have shown that FMT plus immune checkpoint inhibitors (ICI) could improve ⍺PD-1 response in melanoma. The microbiome and shift, along with the clinical impact of non-small cell lung cancer (NSCLC) combination ⍺PD-1+⍺CTLA-4 (dual ICI) melanoma is unknown. Methods: 20 patients (pts) advanced NSCLC treated first-line (1L) 1L dual ICI were recruited. from 1 healthy donor (HD) was administered orally to each pt post bowel prep. week later initiated. A total 11 different HD...
Abstract Background: Several trials combining microbiome-based interventions with immune checkpoints inhibitors (ICI) are currently underway. Previous studies showed the potential of fecal microbiota transplant (FMT) to circumvent secondary anti-PD-1 resistance or improve first-line response in patients advanced melanoma. Whether FMT can be used safely combination anti-PD-1/anti-CTLA-4 (dual ICI) and its impact on microbiome composition remain unknown. Here, we report results from dual ICI...